Abstract
Background: Breast cancer is the most common kind of cancer among women in the world. Despite major cancer therapy successes in recent years, cancer cells usually develop mechanisms to survive chemotherapy- induced cell death. Therefore, new strategies are needed to reverse cancer chemoresistance.
Objective: The aim of this study was to investigate the effect of a recently-synthesized ferrocene derivative named 1-ferrocenyl-3-(4-methylsulfonylphenyl)propen-1-one (FMSP) on cisplatin resistance in MCF-7 cells, focusing on its inhibitory effects on Multi-Drug Resistance-1 (MDR-1) and inflammatory-related STAT3 pathway.
Methods: Cisplatin-resistant MCF-7 cells were developed and the effect of cisplatin and FMSP on cell viability was examined by MTT assay. RT-PCR and Western blotting analyses were performed to assess the gene and protein expression of MDR-1 as well as phosphorylation of JAK2 and STAT3.
Results: Overexpression of MDR1 as well as a marked increase in the level of phosphorylated STAT3 was observed in cisplatin-resistant MCF-7 (MCF-7R) cells. FMSP successfully reduced the MCF-7R cell viability and reversed both MDR1 expression and STAT3 phosphorylation status through which sensitivity of MCF-7R cells to cisplatin treatment was regained.
Conclusion: Our results indicated that FMSP may be considered as a promising therapeutic agent for the prevention and management of chemoresistance in breast cancer cells.
Keywords: Breast cancer, ferrocene, cisplatin, JAK2, STAT3, MDR-1, chemoresistance.
Graphical Abstract
[http://dx.doi.org/10.1111/joim.12084] [PMID: 23844915]
[http://dx.doi.org/10.1016/j.gendis.2018.05.001] [PMID: 30258937]
[http://dx.doi.org/10.1038/s41523-018-0061-y] [PMID: 29644338]
[http://dx.doi.org/10.1038/s41419-019-1689-8] [PMID: 31189884]
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]
[http://dx.doi.org/10.4061/2010/201367] [PMID: 20811617]
[http://dx.doi.org/10.3892/or.2018.6336] [PMID: 29620223]
[http://dx.doi.org/10.1039/C5CS00486A] [PMID: 26486993]
[http://dx.doi.org/10.1016/j.bmc.2014.12.023] [PMID: 25555734]
[http://dx.doi.org/10.1038/s41570-017-0066]
[http://dx.doi.org/10.2174/1871520617666171003145533] [PMID: 28971779]
[http://dx.doi.org/10.2174/1871520620666200101151743] [PMID: 31893999]
[http://dx.doi.org/10.1186/s12935-018-0538-7] [PMID: 29568237]
[http://dx.doi.org/10.1155/2014/476974]
[http://dx.doi.org/10.7150/ijbs.30168] [PMID: 30745853]
[http://dx.doi.org/10.1371/journal.pone.0020965] [PMID: 21677772]
[http://dx.doi.org/10.1016/j.biopha.2018.09.177] [PMID: 30372844]
[http://dx.doi.org/10.1200/JCO.2010.31.8907] [PMID: 22355058]
[http://dx.doi.org/10.1038/28101] [PMID: 9671298]
[http://dx.doi.org/10.20517/cdr.2019.10]
[http://dx.doi.org/10.1186/s12645-017-0030-4] [PMID: 29104700]
[http://dx.doi.org/10.3390/ijms19061690] [PMID: 29882812]
[http://dx.doi.org/10.1016/j.ejmech.2017.02.064] [PMID: 28273561]
[http://dx.doi.org/10.1039/C7MT00183E] [PMID: 28737782]
[http://dx.doi.org/10.1016/j.ejmech.2014.01.043] [PMID: 24561670]
[http://dx.doi.org/10.1016/j.jinorgbio.2014.04.020] [PMID: 24907976]
[http://dx.doi.org/10.18632/oncotarget.19048] [PMID: 28938696]
[http://dx.doi.org/10.1016/j.omtn.2018.01.004] [PMID: 29858050]
[http://dx.doi.org/10.15171/apb.2017.041] [PMID: 29071215]
[http://dx.doi.org/10.1016/j.tips.2015.10.001] [PMID: 26576830]
[http://dx.doi.org/10.5483/BMBRep.2019.52.7.152] [PMID: 31186087]
[http://dx.doi.org/10.1021/acsmedchemlett.6b00046] [PMID: 27326336]
[http://dx.doi.org/10.3390/molecules23092248] [PMID: 30177664]